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Abstract
Rationale: The burden of chronic obstructive pulmonary disease
(COPD) is increasing, yet there are limited data on early life risk
factors.
Objectives: To investigate the role of childhood lung function in
adult COPD phenotypes.
Methods: Prebronchodilator spirometry was performed for a
cohort of 7-year-old Tasmanian children (n = 8,583) in 1968 who
were resurveyed at 45 years, and a selected subsample (n = 1,389)
underwent prebronchodilator and post-bronchodilator
spirometry. For this analysis, COPD was spirometrically deﬁned as
a post-bronchodilator FEV1/FVC less than the lower limit of
normal. Asthma–COPD overlap syndrome (ACOS) was deﬁned as
the coexistence of both COPD and current asthma. Associations
between childhood lung function and asthma/COPD/ACOS were
examined using multinomial regression.
Measurements andMain Results:At 45 years, 959 participants had
neither current asthma nor COPD (unaffected), 269 had current asthma
alone, 59hadCOPDalone, and68hadACOS.The reweightedprevalence
of asthma alone was 13.5%, COPD alone 4.1%, and ACOS 2.9%. The
lowest quartile of FEV1 at 7 years was associated with ACOS (odds ratio,
2.93; 95%conﬁdence interval, 1.32–6.52), butnotCOPDorasthmaalone.
The lowest quartile of FEV1/FVC ratio at 7 years was associated with
ACOS (odds ratio, 16.3; 95% conﬁdence interval, 4.7–55.9) and COPD
(oddsratio,5.76;95%conﬁdence interval, 1.9–17.4),butnotasthmaalone.
Conclusions:Being in the lowestquartile for lung functionatage7may
have long-term consequences for the development of COPD andACOS
by middle age. Screening of lung function in school age children may
identify ahigh-risk group that couldbe targeted for intervention. Further
research is needed to understand possiblemodiﬁers of these associations
and develop interventions for children with impaired lung function.
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Chronic obstructive lung diseases
including asthma and chronic obstructive
pulmonary disease (COPD) are major
public health issues worldwide (1). COPD
is among the leading causes of death, and
asthma also imposes substantial morbidity
and health care costs. Recently, asthma–
COPD overlap syndrome (ACOS) has
received much interest, but its deﬁnition
has been evolving. As deﬁned in the
current joint guideline of Global Initiative
for Asthma and the Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
(1), ACOS is “characterized by persistent
airﬂow limitation with several features
usually associated with asthma and several
features usually associated with COPD.”
Origins of ACOS are complex and still
poorly understood. It is suggested that
ACOS can be the result of progression
from long-term or severe asthma to ﬁxed
airﬂow obstruction (2–5). ACOS may be
simply the coexistence of asthma and
COPD because both conditions are
common. It is also hypothesized that
ACOS is a single disease entity and may
be differentiated from asthma and COPD
by biomarkers, such as exhaled nitric
oxide (6). Compared with asthma or
COPD alone, ACOS is more progressive
in terms of frequency and severity of
exacerbations, hospitalization, and
poor quality of life (7–10).
Determining the causes for ACOS
as opposed to asthma alone or COPD alone
could help guide more targeted prevention
and treatment. The role of early life
determinants of asthma has been widely
studied (11); however, there is increasing
interest in early life origins of COPD. Fixed
airﬂow obstruction is a common feature
of COPD and ACOS, and it is therefore
plausible that early life lung function may
play a role in the etiology of both
conditions.
Longitudinal studies have shown that
poor lung function in early life tracks into
early adulthood (12, 13). Furthermore, it is
now increasingly recognized that people
entering adult life with incomplete lung
growth are at increased risk of COPD, even
in the absence of rapid decline during adult
life (14). A study by Lange and coworkers
(15) of three independent cohorts
compared lung function before the age of
40 years with subsequent lung function
decline and COPD 22 years later. Half the
people with COPD had a normal decline in
FEV1 but started from a lower baseline level
of FEV1. Similarly, another study by Kalhan
and coworkers (16) found that impaired
lung function in subjects between 18 and
30 years of age predicted COPD 20 years
later. The Melbourne Epidemiological
Study of Childhood Asthma (17) reported
that at the age of 50 years, subjects with
COPD or current asthma showed evidence
of lower lung function from childhood
compared with subjects without asthma
and those in remission from asthma, but
ACOS was not examined. It is possible that
lower lung function in early life is related to
COPD and ACOS in adult life, but to date,
no study has directly investigated this
association.
We aimed to investigate associations
between childhood lung function and
current asthma, spirometrically deﬁned
COPD, and ACOS, and to estimate the
prevalence of these conditions in early
middle-age. Some of the results of this study
have been previously reported in the form of
an abstract (18).
Methods
Study Design and Population
This analysis used data from TAHS
(Tasmanian Longitudinal Health Study).
The study methodology has been reported
in detail elsewhere (19). In brief, TAHS
began in 1968 when 8,583 Tasmanian
children born in 1961 and attending
school in Tasmania were studied with
surveys and prebronchodilator (BD)
spirometry. The most recent survey started
in 2002 when the original 1968 cohort was
retraced and resurveyed. A sample of
respondents enriched for asthma and
cough participated in a laboratory study
from 2006 to 2008, which included a
questionnaire and pre-BD and post-BD
spirometry. The 1,389 participants with
post-BD spirometry comprise the sample
for this analysis (see METHODS in the online
supplement).
This study was approved by the Human
Ethics Review Committees at The
Universities of Melbourne (approval
number 040375), Tasmania (040375.1),
New South Wales (08094), the Alfred
Hospital (1118/04), and Royal Brisbane and
Women’s Hospital Health Service District
(2006/037).
Lung Function Measurements
Lung function tests, including pre-BD
and post-BD spirometry were conducted
according to the joint American
Thoracic Society and European
Respiratory Society guidelines (20).
The predicted and % predicted values for
spirometry were derived from the Global
Lung Initiative reference equations (21),
which have been validated in an
Australian population (22).
Deﬁnitions
At age 45 years, current asthma was deﬁned
as having a positive response to the question
“have you ever had asthma?” plus any
asthma symptom or asthma medication use
in the last 12 months. Participants who
denied asthma history at 45 years, but had
reported asthma in any of previous follow-
ups and were using asthma medication
at 45 years were also considered as
current asthma
COPD at age 45 years was deﬁned as
post-BD FEV1/FVC less than the Global
Lung Initiative lower limit of normal.
Smoking was not included as a criterion in
the COPD deﬁnition.
Participants were categorized into four
mutually exclusive groups based on their
asthma and COPD status: (1) neither
asthma nor COPD (unaffected), (2) asthma
alone, (3) COPD alone, and (4) ACOS.
Thus, ACOS included all participants with
both COPD and current asthma.
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: People who enter adult life
with lower lung function are at
increased risk of chronic obstructive
pulmonary disease (COPD) in later life
even if the rate of lung function decline
is normal. However, the role of
childhood lung function on the risk of
middle-age COPD phenotypes is not
known.
What This Study Adds to the
Field: We found associations between
childhood lung function and both adult
COPD alone and asthma–COPD
overlap syndrome. This suggests that
prevention of COPD and asthma–
COPD overlap syndrome should be
considered from early life, including
measures targeted at maximization of
childhood lung function.
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Deﬁnitions of other variables are available
in the online supplement.
Statistical Analysis
Characteristics of participants were
compared across four groups deﬁned at
follow-up (45 yr) (unaffected, asthma
alone, COPD alone, and ACOS) using
chi-square tests for categorical variables
and analysis of variance for continuous
variables where appropriate.
Multinomial regression models were
ﬁtted to investigate associations between
childhood lung function parameters at
7 years and asthma/COPD/ACOS at
45 years. Lung function parameters were
converted to % predicted values. Because
associations between childhood lung
function and both ACOS and COPD alone
were nonlinear, quartiles were used.
The ﬁnal multinomial model was adjusted
for childhood lung infections, childhood
asthma, maternal smoking, paternal
smoking during childhood, and
childhood socioeconomic status.
Interactions were tested between childhood
lung function and each of childhood
asthma, maternal asthma, maternal
smoking, paternal smoking during
childhood, childhood lung infections,
and adult active smoking, by including
interaction terms into the model and using
likelihood ratio tests.
Population prevalence and 95%
conﬁdence intervals (CI) for the entire
Tasmanian population born in 1961 were
extrapolated back from the observed
prevalences by reweighting the known
sampling fractions derived from the 1968,
1974, and 2002 surveys.
Lung function from 7 to 45 years
was compared cross-sectionally among the
four designated groups. Missing values for
lung function at 13 and 18 years were
multiply imputed (20 imputations).
All analyses were performed using
Stata version 13.0 (Stata Corp., College
Station, TX).
Results
Population Prevalence of COPD
Alone, ACOS, and Asthma Alone
Of the 1,389 participants with post-BD
lung function data available at 45 years,
1,355 had information about current
asthma status. Of these, 959 participants
had neither current asthma nor COPD
(unaffected), 269 participants had
current asthma alone, 59 participants
had COPD alone, and 68 participants had
ACOS. Once adjusted for the sampling
weights, the prevalence of current
asthma alone was 13.5% (95% CI,
11.8–15.4), COPD alone 4.1% (95%
CI, 3.0–5.5), and ACOS 2.9% (95% CI,
2.2–3.7) (Figure 1). Therefore, among
COPD population, ACOS accounted for
41% [2.9/(2.91 4.1)].
Demographic and Clinical
Characteristics
There was no difference in age among
the four designated groups. More of the
asthma alone group were female than other
groups. History of active smoking was
signiﬁcantly more frequent in ACOS
(73.5%) and COPD alone (73%) than
in unaffected (57%) groups. Childhood
asthma, maternal asthma, and atopy
were more prevalent in the ACOS and
asthma alone groups. Median age
(interquartile range) at asthma onset was 6
(2–24) and 4 (2–11) years for asthma alone
and ACOS participants, respectively.
Childhood lung infection was not
signiﬁcantly different across the four
groups. ACOS and COPD participants
had a higher prevalence of maternal
smoking during childhood. Almost all
ACOS (92.6%) and asthma alone
(80.2%) participants had used inhaled
medicines for breathing problems in the
last 12 months, whereas it was not
reported at all by COPD alone or
unaffected participants. Within each
clinical group, there was a fairly
consistent reduction of post-BD lung
function indices at 45 years compared
with the unaffected group, with ACOS
having the highest reduction, although
not all between-group comparisons
were signiﬁcant (Table 1).
Longitudinal Tracking of Lung
Function among the Designated
Groups
Pre-BD lung function from 7 years to
45 years among study participants is shown
in Figure 2. Participants with ACOS had
the lowest pre-BD FEV1 (% predicted
values) over time. Participants with COPD
alone or ACOS had signiﬁcantly lower pre-
BD FEV1/FVC (% predicted values) at all
four time points compared with unaffected
participants. Participants with COPD alone
had signiﬁcantly higher FVC at 7 and
13 years, whereas ACOS participants had
signiﬁcantly lower FVC at 45 years.
Associations between Childhood
Lung Function and the Designated
Groups
Associations were observed between
FEV1/FVC ratio at 7 years and both
COPD alone (odds ratio [OR], 5.76; 95%
CI, 1.9–17.4) and ACOS (OR, 16.3; 95%
CI, 4.7–55.9), whereas FEV1 at 7 years
was strongly associated with only
ACOS (OR, 2.93; 95% CI, 1.32–6.52)
but not with COPD alone (Table 2). In
contrast, lung function at 7 years was
not associated with current asthma
alone. These ﬁndings did not change
signiﬁcantly after adjustment was
made for active asthma or asthma
severity at 7 years instead of
presence/absence of asthma. Associations
between childhood lung function and
COPD alone, and ACOS remained
signiﬁcant after additional adjustment
for sampling weights.
There was no evidence of effect
modiﬁcation by childhood lung infections,
childhood asthma, maternal asthma,
maternal smoking, or paternal smoking
during childhood on the associations
between childhood lung function and the
disease groups (all P values for
interaction. 0.1).
Because there was a large variation
in childhood lung function values
among the lowest quartiles of FEV1
and FEV1/FVC, a sensitivity analysis
was conducted after excluding those with
less than 80% predicted (n = 76 and n = 13,
respectively). In this analysis, the
79.5% Unaffected
COPD
4.1%
Asthma
13.5%
ACOS
2.9%
Figure 1. Nonproportional Venn diagram of
reweighted population prevalence of asthma,
COPD, and ACOS (sample sizes for unaffected,
asthma alone, COPD alone, and ACOS groups
were 959, 269, 59, and 68, respectively).
ACOS = asthma–COPD overlap syndrome;
COPD = chronic obstructive pulmonary disease.
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observed lowest quartile associations of
FEV1 (ACOS: OR, 2.4; 95% CI, 1.02–5.7)
and FEV1/FVC (COPD alone: OR, 5.2;
95% CI, 1.7–16.0; and ACOS: OR, 15.1;
95% CI, 4.4–52.0) changed only slightly.
Another sensitivity analysis that
excluded remitted asthma from the control
group (the unaffected group) showed
stronger associations. Childhood FEV1 was
associated with ACOS (OR, 7.0; 95% CI,
2.7–18.3 for the lowest vs. the highest
quartile), whereas childhood FEV1/FVC
was associated with COPD (OR, 6.8; 95%
CI, 2.1–21.8 for the lowest quartile) (OR,
3.9; 95% CI, 1.2–13.1 for the second
quartile) and ACOS (OR, 19.1; 95% CI,
5.2–70.5 for the ﬁrst quartile) (OR, 5.3; 95%
CI, 1.2–21.2 for the second quartile).
Potential Effect Modiﬁcation of the
Observed Associations between
Childhood Lung Function and COPD
(and ACOS) by Smoking Status
We further investigated the association
between childhood FEV1/FVC and middle-
age COPD after stratifying by personal
smoking status. We observed ORs of 7.8
(95% CI, 0.95–68; P = 0.06) in never-
smokers and 5.0 (95% CI, 1.4–19; P = 0.02)
in ever-smokers, but the difference in the
estimates was not signiﬁcant (P value for
interaction = 0.9). We also observed a
higher proportion of COPD
never-smokers (64%) than of COPD
ever-smokers (38%) to have lower
childhood FEV1/FVC (see Table E1
in the online supplement).
However, we were unable to conduct
a similar stratiﬁed analysis by smoking
status for the association between childhood
lung function and ACOS because of
limited sample size in the never-smoking
ACOS group.
Comparison of Spirometrically
Deﬁned COPD with GOLD Clinical
Criteria
According to GOLD guidelines for the
diagnosis, management, and prevention
of COPD (23), key indicators for
considering a diagnosis of COPD include
dyspnea, chronic cough, chronic sputum
production, family history of COPD, and a
history of exposure to risk factors for the
disease (i.e., tobacco smoke, smoke from
home cooking and heating fuels, or
occupational dusts and chemicals). An
individual older than 40 years of age
with any of key indicators should be
diagnosed as COPD if spirometry
conﬁrms the presence of persistent airﬂow
limitation. In our study, 95% of COPD
participants (97% of COPD alone and
93% of ACOS) had at least one key
indicator, thus fulﬁlling the GOLD
clinical diagnosis of COPD.
Discussion
Principal Findings
This study shows that lower lung function at
age 7 years is associated with an increased
risk of COPD and ACOS by middle age. To
our knowledge, this is the ﬁrst report of
lower childhood lung function as a risk
factor for adult COPD and ACOS, providing
further evidence on the early life origins of
these diseases.
Deﬁnition of Outcomes
In clinical practice, symptoms and history of
exposure to risk factors are taken into
account in COPD diagnosis. However, in
this study, the deﬁnition of COPDwas solely
based on spirometry to have a sensitive
deﬁnition. Because the population was
relatively young, symptoms were not
included to avoid missing asymptomatic
participants. Smoking was not part of
the deﬁnition to include both
Table 1. Characteristics of Participants According to Outcome Groups
Unaffected
(n = 959)
Asthma
Alone
(n = 269)
ACOS
(n = 68)
COPD
Alone
(n = 59)
Age, yr* 44.8 (0.8) 45.0 (0.9) 45.0 (0.9) 44.8 (0.7)
Female 459 (47.3) 150 (58.1)† 35 (51.5) 21 (35.6)
Smoking history
Never 415 (43) 126 (49) 18 (26.5)† 16 (27)†
Past 295 (30.5) 77 (30) 16 (23.5) 10 (17)
Current 256 (26.5) 54 (21) 34 (50)† 33 (56)†
Lifetime smoking,
pack-years‡
0.7 (0–14) 0 (0–11) 13 (0–30)x 14.7 (0–31)x
Atopic status 481 (50) 177 (69.1)† 54 (80.6)†,jj 32 (54.2)
Post-BD spirometry at
45 yr*
FEV1, L 3.5 (0.7) 3.2 (0.7)
x 2.6 (0.7)x,¶ 3.0 (0.7)x
% predicted 100.6 (11.6) 96.1 (12.4)x 76.6 (15.6) x,¶ 83.9 (13.4)x
FVC, L 4.4 (0.9) 4.1 (0.9)x 4.1 (1.0)¶ 4.7 (1.1)x
% predicted 100.3 (11.5) 97.8 (12.6)x 97.0 (14.3)¶ 103.3 (15.5)
FEV1/FVC 0.80 (0.1) 0.79 (0.1) 0.63 (0.1) 0.65 (0.1)
% predicted 99.9 (5.6) 97.9 (6.3) 78.2 (8.7) 80.9 (6.1)
Predicted LLN** 0.69 (0.005) 0.69 (0.005) 0.69 (0.006) 0.69 (0.005)
Childhood socioeconomic
status
1 (highest level) 214 (23.4) 57 (23.1) 14 (26.4) 10 (15.8)
2 75 (8.2) 23 (9.3) 2 (3.8) 4 (6.3)
3 269 (29.4) 74 (29.9) 17 (32.1) 26 (41.3)
4 256 (28.0) 60 (24.3) 9 (17.0) 16 (25.4)
5 100 (10.9) 33 (13.3) 11 (20.7) 7 (11.1)
Maternal smoking in
childhood
347 (36.8) 87 (35.5) 28 (50.0)† 34 (50.7)†
Maternal asthma 108 (11.5) 47 (19.2)† 17 (25.4)† 10 (17.5)
Childhood asthma 333 (34.5) 111 (43.7)† 38 (55.9)† 24 (41.4)
Childhood lung infections 170 (17.8) 48 (19.0) 10 (17.2) 13 (19.4)
Definition of abbreviations: ACOS = asthma–COPD overlap syndrome; BD = bronchodilator;
COPD = chronic obstructive pulmonary disease; LLN = lower limit of normal.
Data are presented as n (%) unless otherwise indicated.
*Mean (SD).
†P, 0.05 compared with unaffected by Pearson 23 2 chi-square test.
‡Median (interquartile range).
xP, 0.05 compared with unaffected by Bonferroni multiple comparison test.
jjP, 0.05 compared with COPD by Pearson 23 2 chi-square test.
¶P, 0.05 compared with COPD.
**LLN represents the fifth percentile or 1.645 SD below the predicted mean of values.
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smoking-related and non-smoking-related
phenotypes. One might argue that the term
ﬁxed airﬂow limitation or chronic airﬂow
limitation should be used when only the
post-BD spirometry is used to identify the
cases. However, 95% of the participants
categorized as COPD in this study fulﬁlled
the GOLD clinical deﬁnition of COPD as
having at least one key indicator for a
diagnosis of COPD plus ﬁxed airﬂow
limitation (23). Although our deﬁnition
may have overestimated the number of
COPD (and ACOS) participants, this is
likely to be random across exposure
categories. Therefore, if anything, the
associations with childhood lung function
may have been underestimated.
Prevalence of Outcomes
We estimated the reweighted prevalence of
ACOS and COPD alone to be 2.9% and
4.1%, respectively, at 45 years of age. Few
studies have attempted to quantify the
prevalence of ACOS and it would be
expected to vary depending on age and
deﬁnition. Studies have investigated ACOS
among patients with COPD and have
reported its prevalence to be between 15 and
55% (24–27). Our estimate of 41% is within
this range. Whether ACOS can be seen as
an independent disease entity, a form of
severe asthma, or simply coexistence of the
two common conditions remains a
question for debate (7, 8). In our study, the
reweighted prevalence of ACOS is higher
than the probability of having both asthma
and COPD, suggesting that ACOS is not
just the coexistence of asthma and COPD
by chance alone.
Associations between Childhood
Lung Function and COPD and ACOS
Our study is the ﬁrst to examine the link
between early life lung function and ACOS.
We found that ACOS participants showed
evidence of persistently lower FEV1 and
FEV1/FVC from childhood. This suggests
that poorer childhood lung function
tracked to early adult life, leading to
impaired maximally attained lung function.
This in turn leads to poorer lung function
in middle age, even when lung function
decline is not accelerated.
Our ﬁnding on the associations
between lung function at age 7 years and
COPD bridges the gap between earlier
ﬁndings of Stern and coworkers (12) and
others (15, 16). Following the Tucson
birth cohort longitudinally, Stern and
110 %
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COPD alone
ACOS
110 %
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Figure 2. Cross-sectional comparison of prebronchodilator lung function (mean and 95% confidence
interval of % predicted values) for the four designated groups. ACOS = asthma–COPD overlap
syndrome; COPD= chronic obstructive pulmonary disease.
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coworkers (12) reported that poor lung
function shortly after birth tracked to age
22 years. Kalhan and coworkers (16)
reported a link between poor lung function
in early adulthood and subsequent COPD.
Lange and coworkers (15) found half of
COPD cases could be attributed to low lung
function in adulthood even without steeper
lung function decline. Adding to the well-
recognized pathway to COPD from steep
lung function decline, we now provide
evidence of another long-term pathway to
COPD from poor lung function in
childhood. Moreover, our data show that
those who developed COPD by middle age
had persistently lower FEV1/FVC over time
from childhood (Figure 2), which is
consistent with the observation by Tai and
coworkers (17).
This study highlights that low childhood
lung function is a risk factor for COPD (and
ACOS) independent of smoking. It has been
reported that the effect of cigarette smoking
on lung function decline with age is most
evident in young adults with preexisting
airﬂow obstruction (16). Furthermore, it has
also been shown that reduced lung function
in infancy is associated with wheeze at 18
years, only in smokers (28). We observed
the effect of lower childhood lung function
on subsequent COPD to be greater in
never-smokers than ever-smokers but a test
for interaction between childhood lung
function and smoking was not statistically
signiﬁcant. However, the small sample
size might have limited the statistical
power. It is also possible that the intensity
of smoking in smokers may have differed
between our study and others.
A complex relationship exists
among asthma, lung function, COPD,
and ACOS. On one hand, childhood
asthma has been associated with impaired
childhood lung function (29), adult
asthma, and COPD (30). Moreover, poor
lung function has been described as a
marker of asthma severity and more severe
asthma was strongly associated with
COPD (17). However, childhood asthma
or its severity did not confound our
results. On the other hand, both childhood
asthma (31, 32) and poor childhood lung
function (13) may result from impaired
lung function at birth. Therefore, a
synergistic effect between poor childhood
lung function and “early life asthma
background” or “asthma predisposing
factors” may also contribute to COPD and
ACOS development. However, we did not
observe any such effect modiﬁcation by
childhood asthma or maternal asthma.
However, because of the small sample
sizes for the COPD alone and ACOS
groups, we cannot rule out the possibility
of such interaction.
In our study, participants with asthma
or ACOS had the highest prevalence of
atopy as would be expected. However, the
prevalence of atopy was also high in COPD
and unaffected participants. This is partly
because our sample was enriched for asthma
and cough. However, our reweighted
population prevalence of atopy was also
high, which is consistent with Australia
being among countries with the highest
prevalence of atopy (33). We did not
observe atopy to be an effect modiﬁer for
associations between childhood lung
function and COPD or ACOS.
The age of the participants in our study
was younger than in most clinical trials in
COPD. Our participants, therefore, may
represent an early form/stage of COPD of
relatively low prevalence. Consistently,
mild COPD was predominant in our
study, with 70% of the COPD alone
group having FEV1 greater than or equal
Table 2. Association between Childhood Lung Function and Adult Asthma Alone, COPD Alone, and Asthma–COPD Overlap
Syndrome
Asthma Alone ACOS COPD Alone
n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
FEV1% predicted at 7 yr
Highest (fourth) quartile
(107–137)
53 (23) 1 10 (17) 1 13 (25) 1
Third quartile (98.8–107.0) 61 (27) 1.32 (0.85–2.04) 10 (17) 0.96 (0.36–2.57) 13 (25) 0.92 (0.39–2.16)
Second quartile (90.4–98.8) 53 (23) 1.11 (0.70–1.75) 11 (18) 1.22 (0.48–3.06) 10 (20) 0.80 (0.33–1.98)
First quartile (54.0–90.4) 61 (27) 1.10 (0.70–1.75) 29 (48) 2.93 (1.32–6.52)* 15 (29) 1.09 (0.46–2.55)
FEV1/FVC % predicted at 7 yr
Highest (fourth) quartile
(104.5–113)
52 (23) 1 3 (5) 1 5 (10) 1
Third quartile (100.9–104.5) 64 (28) 1.00 (0.65–1.54) 7 (12) 2.09 (0.51–8.5) 8 (16) 2.25 (0.67–7.4)
Second quartile (96.5–100.9) 51 (22) 0.88 (0.56–1.36) 11 (18) 3.32 (0.86–12.7) 14 (27) 2.76 (0.86–8.9)
First quartile (67.2–96.5) 61 (27) 1.03 (0.65–1.61) 39 (65) 16.3 (4.7–55.9)† 24 (47) 5.76 (1.90–17.4)*
FVC % predicted at 7 yr
Highest (fourth) quartile
(105–146)
62 (27) 1 17 (28) 1 20 (39) 1
Third quartile (97.7–105) 52 (23) 0.91 (0.58–1.41) 12 (20) 0.54 (0.24–1.23) 7 (14) 0.32 (0.13–0.78)‡
Second quartile (90.1–97.7) 57 (25) 0.94 (0.60–1.48) 16 (27) 0.72 (0.33–1.58) 14 (27) 0.46 (0.20–1.05)
First quartile (54.2–90.1) 57 (25) 0.91 (0.58–1.43) 15 (25) 0.68 (0.31–1.47) 10 (20) 0.41 (0.17–0.97)‡
Definition of abbreviations: ACOS = asthma–COPD overlap syndrome; CI = confidence interval; COPD = chronic obstructive pulmonary disease;
OR = odds ratio.
Data are presented with healthy participants as reference group, adjusting for childhood lung infection, childhood asthma, maternal smoking, paternal
smoking, and childhood socioeconomic status.
*P, 0.01.
†P, 0.001.
‡P, 0.05.
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to 80% of predicted values, which is
substantially higher than reported
elsewhere (34, 35). Moreover, we observed
that participants with COPD alone did not
report any medication use for breathing
problems in the prior year. Reporting no
medication use could just reﬂect
underdiagnosis and undertreatment, which
is common in early COPD (35–37).
Strengths and Limitations
Our study has strengths and limitations.
The main strength is that TAHS is one of
the world’s longest-running cohort studies
in which data on lung function and
respiratory health have been collected
prospectively from childhood. Using
information about asthma status at
multiple follow-ups helps minimize
misclassiﬁcation of asthma because of
recall bias (38). The use of post-BD
spirometry to deﬁne COPD at age 45 years
is also a strength of this study compared
with the use of pre-BD spirometry by
other studies (2), which also looked at
COPD and ACOS.
The relatively small sample sizes for
the ACOS and COPD alone groups are a
limitation. In addition, like most other
studies initiated in that era, we did not have
post-BD spirometry at 7 years. However,
any potential that our data were confounded
by the BD response that might have been
seen in more active asthma was taken into
account by analyses allowing for the
presence of childhood asthma and asthma
severity. There was a large variation in lung
function values in the lowest quartiles of
FEV1 and FEV1/FVC, but the sensitivity
analysis conﬁrmed that our observed
associations were not driven by those with
extremely low lung function.
Conclusions
Our study is the ﬁrst to show that lower lung
function in early life may have long-term
consequences for the development of COPD
and ACOS by middle age. Our study
suggests that screening of lung function in
school-age children may provide an
opportunity to detect children likely to
have ongoing poorer lung health, such as
those with lung function below the
lower limit of normal. Multifaceted
intervention strategies could then be
implemented to reduce the burden of
COPD and ACOS in adulthood.
Further research is needed to better
understand the risk factors for lower
lung function in children and also further
understanding of risk factors over adulthood
that interact with lower lung function to
increase the risk of rapid lung function
decline. n
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